PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2018.1172019512502-509Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or ErlotinibYoujin Kim, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sunhttp://e-crt.org/upload/pdf/crt-2018-117.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2018.117, http://www.e-crt.org/upload/pdf/crt-2018-117.pdf
Reactions Weekly10.1007/s40278-018-47032-520181705115-15Afatinib/erlotinib/gefitinibhttp://link.springer.com/content/pdf/10.1007/s40278-018-47032-5.pdf, http://link.springer.com/article/10.1007/s40278-018-47032-5/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-018-47032-5.pdf
Lung Cancer10.1016/s0169-5002(20)30130-62020139S44Afatinib in EGFR mutant non-small-cell carcinoma: Milton Keynes experienceS.A. Rizvi, M. Karinahttps://api.elsevier.com/content/article/PII:S0169500220301306?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301306?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2007.05.0182007583414-417Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancerJohn Wen-Cheng Chang, Chun-Liang Chou, Shiu-Feng Huang, Hung-Ming Wang, Jia-Juan Hsieh, Todd Hsu, Yun-Chung Cheunghttps://api.elsevier.com/content/article/PII:S0169500207003133?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500207003133?httpAccept=text/plain
Value in Health10.1016/j.jval.2016.09.22532016197A740-A741Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR MutationsMS Holleman, R Zaim, CA Uyl-De Groothttps://api.elsevier.com/content/article/PII:S1098301516336191?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301516336191?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2010.05.0152010693259-264Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancerEckart Laack, Guido Sauter, Carsten Bokemeyerhttps://api.elsevier.com/content/article/PII:S0169500210002308?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500210002308?httpAccept=text/plain
Reactions Weekly10.1007/s40278-021-92584-120211847127-27Afatinib/erlotinib/gefitinibhttp://link.springer.com/content/pdf/10.1007/s40278-021-92584-1.pdf, http://link.springer.com/article/10.1007/s40278-021-92584-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-021-92584-1.pdf
OncoTargets and Therapy10.2147/ott.s7538820151137Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitorsJ├ęssica Gomes, Marcelo Cruzhttps://www.dovepress.com/getfile.php?fileID=25113
Lung Cancer10.1016/j.lungcan.2016.05.0022016991-3Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancerYoshitaka Zenke, Shigeki Umemura, Eri Sugiyama, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Koichi Gotohttp://api.elsevier.com/content/article/PII:S0169500216303142?httpAccept=text/xml, http://api.elsevier.com/content/article/PII:S0169500216303142?httpAccept=text/plain
Journal of Cancer Therapy10.4236/jct.2012.32406020120304467-476Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled TrialsAdnan Aydinerhttp://www.scirp.org/journal/PaperDownload.aspx?DOI=10.4236/jct.2012.324060, http://www.scirp.org/journal/doi.aspx?DOI=10.4236/jct.2012.324060, http://www.scirp.org/journal/doi.aspx?DOI=10.4236/jct.2012.324060